dc.contributor.author
Herzig-Nichtweiß, Julia
dc.contributor.author
Salih, Farid
dc.contributor.author
Berning, Sascha
dc.contributor.author
Malter, Michael P.
dc.contributor.author
Pelz, Johann O.
dc.contributor.author
Lochner, Piergiorgio
dc.contributor.author
Wittstock, Matthias
dc.contributor.author
Günther, Albrecht
dc.contributor.author
Alonso, Angelika
dc.contributor.author
Fuhrer, Hannah
dc.contributor.author
Schönenberger, Silvia
dc.contributor.author
Petersen, Martina
dc.contributor.author
Kohle, Felix
dc.contributor.author
Müller, Annekatrin
dc.contributor.author
Gawlitza, Alexander
dc.contributor.author
Gubarev, Waldemar
dc.contributor.author
Holtkamp, Martin
dc.contributor.author
Vorderwülbecke, Bernd J.
dc.contributor.author
IGNITE! study group
dc.date.accessioned
2025-09-17T11:39:19Z
dc.date.available
2025-09-17T11:39:19Z
dc.identifier.uri
https://refubium.fu-berlin.de/handle/fub188/49378
dc.identifier.uri
http://dx.doi.org/10.17169/refubium-49100
dc.description.abstract
Background Acute symptomatic epileptic seizures are frequently seen in neurocritical care. To prevent subsequent unprovoked seizures, long-term treatments with antiseizure medications are often initiated although supporting evidence is lacking. This study aimed at prospectively assessing the risk of unprovoked seizure relapse with respect to the use of antiseizure medications. It was hypothesized that after a first acute symptomatic seizure of structural etiology, the cumulative 12-month risk of unprovoked seizure relapse is & LE; 25%.MethodsInclusion criteria were age & GE; 18 and acute symptomatic first-ever epileptic seizure; patients with status epilepticus were excluded. Using telephone and mail interviews, participants were followed for 12 months after the acute symptomatic first seizure. Primary endpoint was the occurrence and timing of a first unprovoked seizure relapse. In addition, neuro-intensivists in Germany were interviewed about their antiseizure treatment strategies through an anonymous online survey.ResultsEleven of 122 participants with structural etiology had an unprovoked seizure relapse, resulting in a cumulative 12-month risk of 10.7% (95%CI, 4.7%-16.7%). None of 19 participants with a non-structural etiology had a subsequent unprovoked seizure. Compared to structural etiology alone, combined infectious and structural etiology was independently associated with unprovoked seizure relapse (OR 11.1; 95%CI, 1.8-69.7). Median duration of antiseizure treatment was 3.4 months (IQR 0-9.3). Seven out of 11 participants had their unprovoked seizure relapse while taking antiseizure medication; longer treatment durations were not associated with decreased risk of unprovoked seizure relapse. Following the non-representative online survey, most neuro-intensivists consider 3 months or less of antiseizure medication to be adequate.ConclusionsEven in case of structural etiology, acute symptomatic seizures bear a low risk of subsequent unprovoked seizures. There is still no evidence favoring long-term treatments with antiseizure medications. Hence, individual constellations with an increased risk of unprovoked seizure relapse should be identified, such as central nervous system infections causing structural brain damage. However, in the absence of high-risk features, antiseizure medications should be discontinued early to avoid overtreatment.
en
dc.rights.uri
https://creativecommons.org/licenses/by/4.0/
dc.subject
Acute symptomatic seizure
en
dc.subject
Antiseizure medication
en
dc.subject
Cerebrovascular accident
en
dc.subject
CNS infection
en
dc.subject
Ischemic stroke
en
dc.subject
Secondary seizure prophylaxis
en
dc.subject
Seizure risk
en
dc.subject
Structural brain damage
en
dc.subject
Unprovoked seizure
en
dc.subject.ddc
600 Technik, Medizin, angewandte Wissenschaften::610 Medizin und Gesundheit::610 Medizin und Gesundheit
dc.title
Prognosis and management of acute symptomatic seizures: a prospective, multicenter, observational study
dc.type
Wissenschaftlicher Artikel
dcterms.bibliographicCitation.articlenumber
85
dcterms.bibliographicCitation.doi
10.1186/s13613-023-01183-0
dcterms.bibliographicCitation.journaltitle
Annals of Intensive Care
dcterms.bibliographicCitation.number
1
dcterms.bibliographicCitation.originalpublishername
Springer Nature
dcterms.bibliographicCitation.volume
13
refubium.affiliation
Charité - Universitätsmedizin Berlin
refubium.funding
Springer Nature DEAL
refubium.resourceType.isindependentpub
no
dcterms.accessRights.openaire
open access
dcterms.bibliographicCitation.pmid
37712992
dcterms.isPartOf.eissn
2110-5820